Cancer Rop Co. Ltd. (180400) - Total Assets
Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) holds total assets worth ₩115.39 Billion KRW (≈ $78.20 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Cancer Rop Co. Ltd. to assess how comfortably operating cash covers total debt obligations.
Cancer Rop Co. Ltd. - Total Assets Trend (2014–2025)
This chart illustrates how Cancer Rop Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See Cancer Rop Co. Ltd. net assets for net asset value and shareholders' equity analysis.
Cancer Rop Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Cancer Rop Co. Ltd.'s total assets of ₩115.39 Billion consist of 74.2% current assets and 25.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 66.8% |
| Accounts Receivable | ₩3.44 Billion | 2.2% |
| Inventory | ₩2.50 Billion | 1.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩14.81 Billion | 9.6% |
| Goodwill | ₩360.12 Million | 0.2% |
Asset Composition Trend (2014–2025)
This chart illustrates how Cancer Rop Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cancer Rop Co. Ltd. (180400) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cancer Rop Co. Ltd.'s current assets represent 74.2% of total assets in 2025, an increase from 46.7% in 2014.
- Cash Position: Cash and equivalents constituted 66.8% of total assets in 2025, up from 31.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 9.6% of total assets.
Cancer Rop Co. Ltd. Competitors by Total Assets
Key competitors of Cancer Rop Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
Cancer Rop Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.08 | 1.09 | 20.23 |
| Quick Ratio | 4.89 | 0.86 | 19.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩61.50 Billion | ₩2.46 Billion | ₩16.99 Billion |
Cancer Rop Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Cancer Rop Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 114.0% |
| Total Assets | ₩154.87 Billion |
| Market Capitalization | $143.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cancer Rop Co. Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cancer Rop Co. Ltd.'s assets grew by 114.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual total assets of Cancer Rop Co. Ltd. from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩154.87 Billion ≈ $104.96 Million |
+114.04% |
| 2024-12-31 | ₩72.36 Billion ≈ $49.04 Million |
-27.59% |
| 2023-12-31 | ₩99.94 Billion ≈ $67.73 Million |
+16.27% |
| 2022-12-31 | ₩85.95 Billion ≈ $58.25 Million |
+27.25% |
| 2018-12-31 | ₩67.54 Billion ≈ $45.77 Million |
+18.01% |
| 2017-12-31 | ₩57.23 Billion ≈ $38.79 Million |
+92.73% |
| 2016-12-31 | ₩29.70 Billion ≈ $20.13 Million |
+33.93% |
| 2015-12-31 | ₩22.17 Billion ≈ $15.03 Million |
+187.78% |
| 2014-12-31 | ₩7.70 Billion ≈ $5.22 Million |
-- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more